AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05025449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Focused Assessment with Sonography for Trauma (FAST)
Description: The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
Study NCT05025449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bubble-Enhanced FAST (BEFAST)
Description: Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
Study NCT05681741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: current versus high pump flow
Description: during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
Study NCT04861740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Intervention
Description: Autism screening intervention only.
Study NCT04903483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bispectral index monitoring
Description: intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
Study NCT05623280 — intervention group
Intervention type: DRUG
Intervention: Indocyanine green
Description: Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
Study NCT06306859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using m-health for monitoring and education provision
Description: The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence
Study NCT06306859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The comparator group will be given standard and routine care
Study NCT06473519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF MDV
Description: RSVpreF with 2-PE formulated in an MDV
Study NCT06473519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF SDV
Description: RSVpreF without 2-PE formulated in an SDV
Study NCT05582616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: See treatment arm description
Study NCT05582616 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: See sham comparator arm description
Study NCT06631781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GOLD-Cog+
Description: 6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Demographic Data
Description: Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Disease History
Description: The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test will be performed with a spirometer.
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Reaction Time
Description: Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Functional Capacity
Description: Functional capacity will be evaluated with 6 minute walk test
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Dyspnea Perception
Description: Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Quality of Life
Description: Quality of life will be assessed with the Quality of Life Scale for Children\&#34;
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Fear of movement
Description: Fear of movement will be evaluated with Tampa Kinesiophobia Scale
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Ability of Motor Imagery
Description: Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery
Study NCT06630403 — intervention group
Intervention type: OTHER
Intervention: Cognitive Functions
Description: Cognitive functions will be assessed with Trail Making Test and Stroop Test
Study NCT06172595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FET PET
Description: There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
Study NCT04966156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaRE-4-alloBMT plus usual care group
Description: CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography with afterload change
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Stress-MRI
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetocardiography
Description: Magnetocardiography
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Histological analysis
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetics
Description: miRNA sequencing
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: calcium signaling
Description: cardiomyocyte calcium signaling
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IMR
Description: Index of microvascular resistance measurement
Study NCT05826444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Angio-IMR
Description: Angiography derived post-processing index if microvascular resistance
Study NCT03826693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
Study NCT03826693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
Study NCT04656002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
Study NCT05331612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended intervention condition
Description: Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
Study NCT05173493 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin,Furazolidone
Description: Amoxicillin-Furazolidone-containing quadruple group
Study NCT05173493 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin,Levofloxacin
Description: Amoxicillin-Levofloxacin-containing quadruple group
Study NCT05173493 — intervention group
Intervention type: DRUG
Intervention: Tetracycline,Furazolidone
Description: Tetracycline-Furazolidone-containing quadruple group
Study NCT04861740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Intervention
Description: Autism screening intervention only.
Study NCT06025552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU7710
Description: In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
Study NCT05849207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
Study NCT06098573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Alert
Description: Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app \[CIAS\]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
Study NCT06631859 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cosmetic products containing 0% Assam tea
Description: Cosmetic products containing 0% Assam tea
Study NCT06631859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic products containing 2.5% Assam tea
Description: Cosmetic products containing 2.5% Assam tea
Study NCT04515394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
Study NCT04760301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local tranexamic acid injection
Description: local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
Study NCT04760301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: local normal saline injection to cervix
Description: local normal saline injection to the cervix- 20 ml saline
Study NCT04760301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV 1 g tranexamic acid
Description: IV 1 g tranexamic acid diluted in 100 ml saline
Study NCT04760301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV 1 g normal saline
Description: IV 100 ml normal saline
Study NCT04515394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
Study NCT06558591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation intervention
Description: Inclusion will take place within the framework of routine care for individuals with chronic diseases in rehabilitation services, hospitals, institutions, etc. The study will be offered to patients with chronic illnesses who are being cared for by their therapists. Data collection will be conducted in two sessions. The period between the two sessions will be determined based on the patient's availability, not exceeding a period of 12 weeks:~1. 1st session at 0 week : Conducting activities and initial evaluation at their usual care center. Therapists will perform the various planned tests and evaluations.~2. 2nd session at 12 weeks : This session will take place under the same conditions as the first one and without any potential health risks to the participants.~3. A final evaluation will be carried out at the 18-week follow-up. A telephone call will be made between sessions to check in and assist participants in case of any issues during the study.
Study NCT06240039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon
Description: The experimental days consist of four study days:~1. Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~2. Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~3. Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~4. Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes.
Study NCT05560828 — intervention group
Intervention type: OTHER
Intervention: Zio XT service
Description: There will be no intervention. Standard of care at participating NHS organizations will not be affected.
Study NCT05390476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 500mg orally three times a day (continuously)
Study NCT05390476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 500mg orally three times a day (continuously)
Study NCT05390476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
Study NCT05100966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FitJoints Multi-modal Intervention
Description: Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization.
Study NCT06025552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
Study NCT04749979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist (decapeptyl )
Description: giving agonist
Study NCT04749979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG ( eg. Choriomon )
Description: giving HCG
Study NCT04615689 — intervention group
Intervention type: OTHER
Intervention: The collection of feces
Description: When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.
Study NCT06033196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more
Study NCT06033196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tocilizumab
Description: Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses
Study NCT04135365 — intervention group
Intervention type: BEHAVIORAL
Intervention: neurocognitive assessment
Description: Observational study therefore there are no interventions
Study NCT04135365 — intervention group
Intervention type: BEHAVIORAL
Intervention: neuroimaging assessment
Description: Observational study therefore there are no interventions
Study NCT05251246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recovery management program
Description: The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
Study NCT06069531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract
Description: Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
Study NCT06069531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract
Description: Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
Study NCT04619654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold
Description: Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
Study NCT05403658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigation
Description: FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
Study NCT05403658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.